Posted by Michael Wonder on 07 May 2017
ALK's HDM SLIT-tablet Acarizax approved in Canada
4 May 2017 - ALK today announced that its house dust mite sub-lingual allergy immunotherapy tablet Aacazix has been approved in Canada.
The new drug submission for Acarizax was filed with Health Canada in May 2016.
Acarizax is indicated as allergy immunotherapy for the treatment of moderate to severe house dust mite-induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age confirmed by a positive skin prick test and/or in vitro testing for D. farinae or D. pteronyssinus IgE antibodies.
